FDA has spurred investment to create and develop 600 therapies: As new manufacturing processes and technologies are introduced to meet demand and overcome challenges, understanding also needs to improve to ensure the right balance is achieved.
| Publicado en: | Pharmaceutical Technology Vol. 47; no. 4; pp. 16 - 19 |
|---|---|
| Autor principal: | |
| Formato: | pictorial Journal Article |
| Publicado: |
MJH Life Sciences
Apr2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162989682&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 162989682 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15432521 4FK jtl: Pharmaceutical Technology issn: 15432521 maglogo: N pubinfo: dt: Apr2023 vid: 47 iid: 4 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 162989682 162989682 162989682 162989682 ppf: 16 ppct: 3 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: FDA has spurred investment to create and develop 600 therapies: As new manufacturing processes and technologies are introduced to meet demand and overcome challenges, understanding also needs to improve to ensure the right balance is achieved. aug: au: Thomas, Felicity sug: subj: United States Food and Drug Administration Investments Pharmaceutical Companies Economics Drug Development Technology, Pharmaceutical Economics COVID-19 Pandemic Uncertainty Manufacturing Industry Cost Benefit Analysis Quality Control (Technology) Collaboration pubtype: Trade Publication doctype: pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|